This unique biotech play should rally more than 35% ahead, BTIG says
The Wall Street firm said this stock is a category leader for model-informed drug development (MIDD), or simulations for biotech drug trials.
Source: cnbc.com
Page 23 - Simulations Plus Inc News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Simulations Plus Inc. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Simulations Plus Inc Today - Breaking & Trending Today
Simulations Plus, Inc. (NASDAQ:SLP) Director Walter S. Woltosz Sells 20,000 Shares
Simulations Plus, Inc. (NASDAQ:SLP – Get Rating) Director Walter S. Woltosz sold 20,000 shares of the firm’s stock in a transaction dated Wednesday, April 26th. The stock was sold at an average price of $41.52, for a total transaction of $830,400.00. Following the completion of the transaction, the director now directly owns 3,875,739 shares in […]
Source: wkrb13.com
Simulations Plus Receives U.S. FDA Renewal for DILIsym Software Licenses
Provides FDA with software tools to investigate drug-induced liver injury in clinical trials ... | April 18, 2023
Source: marketscreener.com
Simulations Plus, Inc. (NASDAQ:SLP) Q2 2023 Earnings Call Transcript
Operator: Greetings, and welcome to the Simulations Plus Second Quarter Fiscal 2023 Financial Results Conference Call. At this time, all participants are in a listen-only mode.
Source: insidermonkey.com
Insider Selling: MongoDB, Inc. (NASDAQ:MDB) Director Sells $268,287.75 in Stock
Simulations Plus (NASDAQ:SLP – Get Rating) issued an update on its FY 2023 earnings guidance on Wednesday morning. The company provided earnings per share (EPS) guidance of $0.63-$0.67 for the period, compared to the consensus estimate of $0.65. The company issued revenue guidance of $59.30 million-$62.00 million, compared to the consensus revenue estimate of $60.79 […]
Source: dailypolitical.com